Insights On Drug Development

  1. A New Look At Subcutaneous mAb Delivery Using Nanoformed Particles 6/3/2025

    A highly concentrated non-aqueous suspension of an IgG1 was developed using a patented platform. Review how the particle size of the mAb impacts the overall behavior of the drug product.

  2. Leveraging Robust Immunogenicity Assessments To Mitigate Clinical Risks 6/2/2025

    By improving the granularity and interpretability of preclinical immunogenicity data, EpiScreen® 2.0 supports more confident lead selection and helps mitigate downstream clinical risks.

  3. Key Bioassay Strategies For Successful IND Submission 6/2/2025

    Watch Erika Kovacs, Senior Director of Bioassay, as she discusses critical considerations for developing stage-appropriate bioassays to support complex biologics and bioconjugates on the path to IND.

  4. Advancements In Evaluating Fc-Mediated Functional Activity In Biologics 6/2/2025

    Watch this presentation to gain a comprehensive overview of how to evaluate Fc-mediated functions — and why doing so is vital to the success of biologic therapies.

  5. Timing Is Everything: Choosing The Right Bioassay To Increase Success 6/2/2025

    Discover how phase-appropriate bioassays deliver regulatory-compliant, decision-ready data — from early discovery to commercial production.

  6. External Partners Are Relational And Technical 5/29/2025

    Jumai Abioye, Founder and CEO, Pan Access Innovations Inc. provides opening comments on CMC needs and gaining support from your CDMOs.

  7. When Outsourcing, Take Advantage Of Each Other's Strengths 5/29/2025

    Bikash Chatterjee, President and Chief Science Officer, Pharmatech Associates, says sponsors and CDMOs have different business models and strengths, and that is a good thing to exploit.

  8. Key Considerations For Cell Therapy Outsourcing 5/29/2025

    During a recent Outsourced Pharma Live, one of our speakers provided some key points to consider if you are a cell-therapy organization relying on CDMOs.

  9. Scarce Money And Resources? You Still Have To Prepare For Working With CDMOs 5/29/2025

    More outsourcing, but often less financing and a leaner internal staff. What's a biotech to do? Prepare carefully to outsource. Here, speakers discuss how to do that.

  10. Should Your CDMO Run 'Technical' Batches? 5/29/2025

    Our panel pitches in on the need for "extra" technical, tox or engineering batches to further ensure manufacturing success, and considering tight budgets at biotechs.